Department of Sexology, University Hospital of Copenhagen, Copenhagen, Denmark.
Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
Sex Med. 2016 Mar;4(1):e60-8. doi: 10.1016/j.esxm.2016.01.001.
Studies of mortality and somatic well-being after sex-reassignment surgery (SRS) of transsexual individuals are equivocal. Accordingly, the present study investigated mortality and somatic morbidity using a sample of transsexual individuals who comprised 98% (n = 104) of all surgically reassigned transsexual individuals in Denmark.
To investigate somatic morbidity before and after SRS and cause of death and its relation to somatic morbidity after SRS in Danish individuals who underwent SRS from 1978 through 2010.
Somatic morbidity and mortality in 104 sex-reassigned individuals were identified retrospectively by data from the Danish National Health Register and the Cause of Death Register.
Somatic morbidity and cause of death.
Overall, 19.2% of the sample were registered with somatic morbidity before SRS and 23.1% after SRS (P = not significant). In total, 8.6% had somatic morbidity before and after SRS. The most common diagnostic category was cardiovascular disease, affecting 18 individuals, 9 before and 14 after SRS, and 5 of those 14 who were affected after SRS had cardiovascular disease before and after SRS. Ten individuals died after SRS at an average age of 53.5 ± 7.9 years (male to female) and 53.5 ± 7.3 years (female to male).
Of 98% of all Danish transsexuals who officially underwent SRS from 1978 through 2010, one in three had somatic morbidity and approximately 1 in 10 had died. No significant differences in somatic morbidity or mortality were found between male-to-female and female-to-male individuals. Despite the young average age at death and the relatively larger number of individuals with somatic morbidity, the present study design does not allow for determination of casual relations between, for example, specific types of hormonal or surgical treatment received and somatic morbidity and mortality.
关于跨性别个体接受性别重置手术后(SRS)的死亡率和躯体健康状况的研究结果存在争议。因此,本研究通过丹麦所有接受过 SRS 的跨性别个体中占 98%(n=104)的样本,调查了 SRS 前后的躯体发病率和死亡率,以及 SRS 后死亡率与躯体发病率的关系。
调查 1978 年至 2010 年间接受 SRS 的丹麦个体的 SRS 前后躯体发病率和死亡率,以及 SRS 后死亡率与躯体发病率的关系。
通过丹麦国家健康登记处和死因登记处的数据,回顾性地确定 104 名接受过 SRS 的个体的躯体发病率和死亡率。
躯体发病率和死亡率。
总体而言,样本中有 19.2%在 SRS 前有躯体发病率,23.1%在 SRS 后有躯体发病率(P=无显著性差异)。共有 8.6%的个体在 SRS 前后均有躯体发病率。最常见的诊断类别为心血管疾病,共影响 18 人,9 人在 SRS 前,14 人在 SRS 后,其中 14 人中有 5 人在 SRS 前后均患有心血管疾病。10 人在 SRS 后死亡,平均年龄为 53.5±7.9 岁(男变女)和 53.5±7.3 岁(女变男)。
在 1978 年至 2010 年间,所有接受过官方 SRS 的丹麦跨性别者中,有 1/3 的人患有躯体疾病,大约 1/10 的人已经死亡。男变女和女变男个体之间的躯体发病率或死亡率无显著差异。尽管死亡的平均年龄相对较小,且患有躯体疾病的个体数量相对较多,但本研究设计无法确定特定类型的激素或手术治疗与躯体发病率和死亡率之间的因果关系。